$3.41 Billion is the total value of Avoro Capital Advisors LLC's 32 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 88.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | Buy | IMMUNOMEDICS INC | $518,420,000 | +86.2% | 24,500,000 | +16.7% | 15.22% | +31.0% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $496,137,000 | +69.8% | 3,850,200 | +2.7% | 14.57% | +19.5% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $227,110,000 | +79.7% | 1,760,000 | +4.9% | 6.67% | +26.5% |
| CNST | New | CONSTELLATION PHARMACEUTICALS INC | $171,952,000 | – | 3,650,000 | +100.0% | 5.05% | – |
| ARGX | Buy | ARGENX SEsponsored adr | $150,327,000 | +58.0% | 936,500 | +12.2% | 4.41% | +11.2% |
| QURE | Buy | UNIQURE NV | $121,822,000 | +748.0% | 1,700,000 | +365.8% | 3.58% | +497.2% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $109,088,000 | +22.5% | 11,200,000 | +0.9% | 3.20% | -13.7% |
| ZGNX | Buy | ZOGENIX INC | $104,260,000 | +38.9% | 2,000,000 | +6.7% | 3.06% | -2.3% |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $60,480,000 | +161.1% | 5,250,000 | +23.5% | 1.78% | +83.9% |
| DCPH | New | DECIPHERA PHARMACEUTICALS INC | $31,120,000 | – | 500,000 | +100.0% | 0.91% | – |
| CUE | New | CUE BIOPHARMA INC | $29,686,000 | – | 1,870,000 | +100.0% | 0.87% | – |
| MRNS | New | MARINUS PHARMACEUTICALS INC | $13,392,000 | – | 6,200,000 | +100.0% | 0.39% | – |
| TGTX | New | TG THERAPEUTICS INC | $11,100,000 | – | 1,000,000 | +100.0% | 0.33% | – |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $10,780,000 | -22.0% | 5,500,000 | +103.7% | 0.32% | -45.1% |
| DCPH | New | DECIPHERA PHARMACEUTICALS INCcall | $5,010,000 | – | 800,000 | +100.0% | 0.15% | – |
| New | ALIMERA SCIENCES INC | $3,153,000 | – | 415,999 | +100.0% | 0.09% | – | |
| SGEN | New | SEATTLE GENETICS INCcall | $150,000 | – | 75,000 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.